The "Hepatitis D - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report provides comprehensive insights about marketed and Phase III products for Hepatitis D . The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country.
Global API Manufacturers of Marketed Products for Hepatitis D
Coverage of API manufacturers for Hepatitis D marketed products spanning across United States, Europe, China and India. The manufacturers' details include manufacturers' name along with their location.
Emerging Phase III products for Hepatitis D
This report provides a comprehensive understanding of the emerging Phase III therapies for Hepatitis D which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends. Their forecasted global sales are also provided till 2020.
Scope
- A review of the marketed products for Hepatitis D including their description, route of synthesis, regulatory milestones, forecasted sales estimates till 2020 and API manufacturer details.
- Patent information coverage of the marketed products including the patent number, holder, grant and patent expiry details
- API manufacturers for the marketed products with location details
- Emerging Phase III product profiles for Hepatitis D including product description, developmental activities, licensors & collaborators and chemical information
Key Topics Covered
1. Report Introduction
2. Hepatitis D: Overview
- Risk Factors
- Causes
- Symptoms
- Pathophysiology
- Prognosis
- Diagnosis
- Treatment
3. Comparative Analysis of Marketed and Emerging Products
4. Marketed Therapies
4.1. Drug 1: Company name
- Product Description
- Route of Synthesis
- Mechanism of Action
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- Adverse Reactions
- Clinical Trials
- Regulatory Milestones
- Product Development Activities
4.1.1 Product Details
- United States
- Europe
4.1.2 Global Sales Assessment
- Historical Global Sales
- Forecasted Global Sales
4.1.3 Patent Details
Other marketed products in the detailed report
5. Emerging Therapies (Phase III)
5.1 Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
5.1.1 Forecasted Global Sales
Other Phase III profiles in the detailed report
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/mh4m2f/hepatitis_d?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20180720005129/en/
Contacts:
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Infectious
Diseases Drugs, Liver
and Kidney Disorders Drugs